SanticxisHealth Economics ConsultingStrategic health economics consulting
Decide with confidence. Maximize the value of every healthcare investment.
Santicxis supports governments, institutions, industry leaders, and healthcare organizations facing high-stakes decisions under pressure. We turn scientific, economic, and regulatory complexity into defensible, fundable, action-ready decisions.
- Economic evaluation and advanced modeling
- Market access, reimbursement, and public decision support
- Local capacity building and practical knowledge transfer
Positioning
A specialist firm with high strategic value
Rare expertise at the intersection of pharmacoeconomics, health policy, and African and emerging markets.
Clients & partners
Organizations looking for credible, disciplined, decision-shaping expertise
What is really at stake
When resources are constrained, every decision must stand up to scrutiny.
Budget pressure
Innovations are becoming more expensive, public budgets are tighter, and trade-offs are increasingly sensitive.
Evidence requirements
Payers and authorities expect robust, contextualized analyses that are easy to defend.
Reputational risk
Poor allocation choices can slow innovation, weaken a dossier, and expose the final decision.
Authority signals
Credibility built through research, assignments, and public decision support
Capabilities
Services designed to persuade, de-risk, and accelerate decision-making.
Every intervention is shaped as a value lever for your teams, partners, and decision-making bodies.
Economic evaluation & modeling
Maximize the impact of every healthcare investment.
We build and adapt cost-effectiveness, cost-utility, budget impact, and uncertainty models to turn data into defensible strategic choices.
- Tailored models: Markov, decision trees, microsimulation, partitioned survival
- Deterministic and probabilistic sensitivity analyses
- Projection of direct, indirect, and system-wide impacts
Market access & public decision support
Accelerate the adoption of health innovations.
We structure economic arguments, access dossiers, and reimbursement strategies to increase acceptance potential and shorten decision timelines.
- Preparation of robust, context-specific access files
- Pricing, positioning, and reimbursement strategy
- Support for negotiations and decision-maker engagement
Training & capability transfer
Build durable in-house autonomy.
We design executive and technical training in health economics, data analysis, R, Stata, and critical appraisal to strengthen your internal capabilities.
- Tracks for institutions, industry, and academia
- Formats for leaders, experts, and project teams
- Practical, contextualized, directly applicable delivery
Evidence of value
An expertise that speaks to financing, public policy, and real-world adoption.
More credible dossiers
Rigorous analyses that strengthen technical, economic, and institutional defensibility.
Better resource allocation
Actionable recommendations balancing affordability, equity, and health impact.
Less uncertainty, greater buy-in
Clear visibility on scenarios, risks, and room for maneuver to support decision-making.
Christian Kouakou, PhD
Health economist, researcher, and advisor, Christian Kouakou helps decision-makers optimize healthcare investments across francophone and resource-constrained settings.
His work focuses on the economic value of health, QALYs, health technology assessment, and decision-oriented modeling.
His publications in journals such as European Journal of Health Economics, Value in Health, BMJ Open, and IJERPH reinforce the firm’s scientific credibility.
Expertise grounded in published work and methods aligned with international standards.
A strong ability to connect analytical rigor with real payer, regulator, and institutional trade-offs.
A nuanced understanding of health system needs in Africa, Canada, and emerging markets.
Case studies
Case studies
Case studies developed from real assignments and analyses illustrating the value created by Santicxis in economic evaluation, market access, and public health.
Type 2 diabetes: cost-effectiveness evaluation of a new treatment
A ministry of health needs to assess whether a new antidiabetic treatment should enter the reimbursed basket of care despite high cost, budget pressure, and uncertainty around real value.
Key results
- QALY gain: +0.85
- Incremental cost: +$1,020
- ICER: $1,200 per QALY
- Probability of cost-effectiveness: 78% at a $3,000 per QALY threshold
Decision impact
- Strong scientific justification for decision-makers
- Direct support for public decision-making
- Better resource allocation
Oncology: economic evaluation of an innovative treatment
A health authority must rule on the reimbursement of a targeted therapy in a context of high price, high clinical stakes, and strong uncertainty around survival.
Key results
- QALY gain: +1.2
- Incremental cost: +$18,000
- ICER: $15,000 per QALY
- Reduced price scenario: ICER lowered to $9,000
Decision impact
- Clarifies reimbursement conditions
- Provides an objective basis for price negotiation
- Supports better patient targeting to improve efficiency
Vaccination: evaluation of a national public health program
A resource-constrained country is considering the introduction of a new vaccine and must balance upfront cost, population impact, and program sustainability.
Key results
- Incidence reduction: -35%
- Hospitalization reduction: -50%
- ICER: dominant with net savings
Decision impact
- Improves population health
- Reduces hospital costs
- Provides a strong case for funders and financing partners
Rare diseases: reimbursement strategy for a specialized therapy
A manufacturer was preparing the positioning of a therapy intended for a small population, with a high unit cost and promising but still limited clinical data. The challenge was to build a sufficiently robust dossier to reassure payers despite residual uncertainty.
Key results
- Three reimbursement scenarios prioritized according to acceptable risk level
- Clarification of minimum targeting conditions to improve efficiency
- Value narrative refocused on patients with the highest expected benefit
- Reduced rejection risk linked to a request perceived as premature
Decision impact
- Stronger dossier credibility with authorities and payers
- Better control of the price-versus-uncertainty discussion
- Greater ability to negotiate on structured and defensible grounds
Budget prioritization: arbitrating across multiple health interventions
A public institution had to allocate limited resources across several competing interventions, all considered useful but impossible to fund simultaneously at the same level. The need was for a credible prioritization method, readable for decision-makers and publicly defensible.
Key results
- Clear ranking of interventions across three priority levels
- Identification of programs to maintain, expand, or phase
- Improved visibility on trade-offs between equity and efficiency
- Shared discussion basis across technical, financial, and governance actors
Decision impact
- Better internal acceptance of budget decisions
- Improved traceability of arbitration criteria
- Reduced risk of decisions being perceived as arbitrary
Capacity building: structuring an in-house health economics unit
An organization wanted to reduce its dependence on external expertise and build internal capability able to read, challenge, and gradually produce economic analyses useful for decision-making.
Key results
- Definition of a three-phase roadmap for capability scaling
- Clarification of roles between internal expertise, external support, and governance
- Prioritization of early high-value demonstrator deliverables
- Creation of a shared language between technical teams and decision-makers
Decision impact
- Greater autonomy in reading and using economic evidence
- More credible and better sequenced capability-building
- Improved durability of investments in training and technical assistance
Publications, books & articles
Thought leadership that reinforces the credibility of your decisions.
Santicxis does more than deliver analysis. The firm draws on scientific publications, an upcoming reference book, and a structured editorial line to illuminate complex health economics decisions.
Let’s discuss your strategic healthcare priorities.
Need an economic evaluation, a market access strategy, or a high-level training program? Let’s define the intervention that creates the right impact.